1. Home
  2. Analysis
  3. Victoza
  4. Nuplazid

Victoza and Nuplazid drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Victoza (liraglutide) and Nuplazid (pimavanserin tartrate). Common drug interactions include balance disorder among females and blood glucose increased among males.

The phase IV clinical study analyzes what interactions people have when they take Victoza and Nuplazid. It is created by eHealthMe based on reports of 39 people who take the same drugs from the FDA, and is updated regularly.

What is Victoza?

Victoza has active ingredients of liraglutide. It is often used in diabetes. eHealthMe is studying from 42,880 Victoza users. Check the latest studies of Victoza.

What is Nuplazid?

Nuplazid has active ingredients of pimavanserin tartrate. eHealthMe is studying from 47,103 Nuplazid users. Check the latest studies of Nuplazid.

On Jul, 26, 2026

39 people who take Victoza and Nuplazid together, and have interactions are studied.

Victoza and Nuplazid drug interactions.

What are the common drug interactions of Victoza and Nuplazid, by gender? *:

female:

  1. Balance disorder
  2. Hallucination, auditory (perceiving sounds without auditory stimulus)
  3. Fall
  4. Dizziness
  5. Death
  6. Aphasia (damage to the parts of the brain that control language)
  7. Feeding disorder (when children refuse to eat certain food groups)
  8. Gait disturbance
  9. Head injury
  10. Nausea (feeling of having an urge to vomit)

male:

  1. Blood glucose increased
  2. Balance disorder
  3. Death
  4. Hallucination (an experience involving the perception of something not present)
  5. Electrolyte imbalance
  6. Hallucination, visual (seeing things that aren't there)
  7. Dizziness
  8. Gait disturbance
  9. Hospitalisation
  10. Confusional state

What are the common drug interactions of Victoza and Nuplazid, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Blood glucose increased
  2. Muscular weakness (muscle weakness)
  3. Arrhythmia (irregular heartbeat)
  4. Electrolyte imbalance
  5. Gait disturbance
  6. Hallucination, auditory (perceiving sounds without auditory stimulus)
  7. Confusional state
  8. Hallucination (an experience involving the perception of something not present)
  9. Abnormal behaviour
  10. Blood glucose decreased

What are the existing conditions these people have? *

  1. Parkinson's Disease: 28 people, 71.79%
  2. Hallucinations (sensations that appear real but are created by your mind): 16 people, 41.03%
  3. Delusion (a false belief or opinion): 15 people, 38.46%
  4. Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Victoza and Nuplazid?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Victoza and Nuplazid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Victoza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Nuplazid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Victoza and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Nuplazid and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on liraglutide and pimavanserin tartrate (the active ingredients of Victoza and Nuplazid, respectively), and Victoza and Nuplazid (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.